Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-864 in PiZZ Genotype Alpha-1 Antitrypsin Deficiency
NCT04474197Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of VX-864 in alpha-1 antitrypsin deficiency (AATD), sponsored by Vertex Pharmaceuticals. Started Jul 2020; status: completed.
02
Drugs
VX-864
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT04474197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474197.